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Abstract
Advances in nanotechnology have demonstrated potential application of nanoparticles for 
effective and targeted drug delivery. Here, we investigated the antimicrobial and immunological 
properties and the feasibility of using nanoparticles to deliver antimicrobial agents to treat a 
cutaneous pathogen. Nanoparticles synthesized with chitosan and alginate demonstrated a direct 
antimicrobial activity in vitro against Propionibacterium acnes, the bacterium linked to the 
pathogenesis of acne. By electron microscopy imaging, chitosan-alginate nanoparticles were 
found to induce disruption of the P. acnes cell membrane, providing a mechanism for the 
bactericidal effect. The chitosan-alginate nanoparticles also exhibited anti-inflammatory properties 
as they inhibited P. acnes induced inflammatory cytokine production in human monocytes and 
keratinocytes. Furthermore, benzoyl peroxide, a commonly used anti-acne drug, was effectively 
encapsulated in the chitosan-alginate nanoparticles and demonstrated superior antimicrobial 
activity against P. acnes compared to benzoyl peroxide alone while demonstrating less toxicity to 
eukaryotic cells. Together, these data suggest the potential utility of topical delivery of chitosan-
alginate nanoparticle encapsulated drug therapy for the treatment of dermatologic conditions with 
infectious and inflammatory components.
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Introduction
Nanoparticles (NPs) are currently being investigated and used in many areas of medicine to 
allow for specific drug delivery, lower dosing of active agents, combination therapy, 
minimizing side effects, and harnessing more potent drugs which cannot clinically be 
utilized by conventional drug delivery. In response to the growing threat of microbial drug 
resistance, nanotechnology has become a major area of interest due to its many unique 
characteristics. In particular, the physical and chemical properties of nanoparticles, including 
their high surface-tovolume ratio and small size, allows for the ability to surpass barriers and 
gain access to biological molecules and importantly, microorganisms (Blecher et al., 2011). 
This direct interaction with microbial cell membranes/walls and key proteins/enzymes can 
both inhibit pathogen growth and/or instigate cell death through mechanism different from 
our armament of antibiotics, to which resistance has developed. In addition, the size, shape, 
and chemical characteristics of nanoparticles may be manipulated in order to facilitate these 
molecular interactions, optimizing their ultimate action (Blecher et al., 2011; Kim et al., 
2010).
It has become apparent that the development of nanotechnology for the treatment of 
infectious diseases, particularly skin disease, involves two major areas: The first utilizes 
materials that at the nanoscale have inherent antimicrobial properties (Hemmila et al., 2010), 
and the second incorporates known therapeutics into nano-vehicles in order to enhance 
delivery and improve efficacy (Cunha-Azevedo et al., 2011; Dominguez-Delgado et al., 
2011; Kumar et al., 2011). The ideal approach to develop a topical therapy for microbial 
infection in skin would utilize a nanomaterial that has both inherent and potent antimicrobial 
properties and the ability to serve as a nano-vehicle would be ideal.
Chitosan is a natural polysaccharide biopolymer derived from chitin, the principal structural 
component of the crustacean exoskeleton. Depending on the degree of deacetylation, 
chitosan can have an extensive collection of C2 amino groups, having pKa values of ~ 6.5, 
which can become protonated in weakly acidic conditions. It is this polycationic character 
that confers chitosan’s antimicrobial properties, which favors interaction with negatively-
charged microbial cell walls and cytoplasmic membranes. These interactions result in 
decreased osmotic stability, membrane disruption, and eventual leakage of intracellular 
elements (Banergee et al., 2010; Ma et al., 2008; Sanpui et al., 2008). In addition, chitosan 
may enter the nuclei of bacteria and fungi and inhibit mRNA and protein synthesis by 
binding to microbial DNA (Blecher et al., 2011; Ma et al., 2008; Qi et al., 2005). When 
nano-scaled, chitosan has a higher surface to volume ratio, translating into higher surface 
charge density, increased affinity to bacteria and fungi, and greater antimicrobial activity (Qi 
et al., 2005). Even more so, chitosan possesses some immunological functions including 
inhibition of pro-inflammatory cytokines, promotion of tissue granulation via fibroblast 
recruitment (Ueno et al., 2001), and production of type III collagen (Ueno et al., 1999). 
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Together, these data suggest that chitosan can be utilized as an antimicrobial, anti-
inflammatory and wound healing accelerant. However, while gaining a polycationic charge 
in a weakly acidic environment such as one supported by the epidermis, chitosan is weakly 
soluble in physiologic solvents, therefore limiting its clinical use to date (Chavez de Paz et 
al., 2011).
Given chitosan’s antimicrobial and immunological properties, we investigated whether 
chitosan-alginate NPs could be effectively generated, stored, and delivered in physiologic 
parameters ,demonstrate antimicrobial and anti-inflammatory activity against a clinically 
important cutaneous bacterium, P. acnes, and whether these NPs might be a useful approach 
to target acne therapy.
Results
Antimicrobial activity of chitosan-alginate nanoparticles
The primary goals of acne treatment are resolution of inflammatory lesions, prevention of 
future comedo formation and prevention of persistent inflammation (Lee, 2009). Therefore, 
for acne therapy, agents with both antimicrobial and anti-inflammatory properties are highly 
effective. As chitosan has demonstrated antimicrobial activity against various pathogens 
including S. aureus (Jia et al., 2001; Qi et al., 2005) and E. coli (Chen et al., 2002; Sanpui et 
al., 2008), chitosan-alginate NPs were evaluated for their antimicrobial activity against a 
common cutaneous bacterium, P. acnes.
In order to synthesize nontoxic, biodegradable, and biocompatible NPs that can be used for 
the treatment of cutaneous infections, we chose a derivative of the biostructural crustacean 
shell polymer chitin, chitosan, along with the well known thermally stable gelling agent, 
alginate (Sayag et al., 1996). The synthesis of the chitosan-alginate nanoparticles was 
demonstrated to be successful using transmission electron microscopy (TEM) visualization 
that showed the majority of individual NPs were less than 50 nm diameter (Figure 1a). 
Using dynamic light scattering, particles were found to have an average hydrodynamic 
diameter of 341.6 ± 11.1nm (Figure 1b) with a polydispersity of 23.7. This is not surprising 
as measurements are taken in water and chitosan nanoparticles have been shown to swell 
rapidly in this setting (Gelfuso et al., 2011; Jayakumar et al., 2011)
To measure the antimicrobial activity against P. acnes, we incubated the bacteria with 
varying doses of chitosan-alginate NPs, as well as with chitosan and alginate control alone 
for four hours. Subsequently, the bacteria were plated and the viability was determined by 
colony forming unit (CFU) assay. The chitosan-alginate NPs were effective at inhibiting the 
growth of P. acnes in a dose-dependent manner and by approximately four logs at the most 
concentrated dose of NPs tested (Figure 2). We also demonstrated that chitosan alone could 
inhibit the growth of P. acnes by a 5.0 log decrease but alginate had no effect on the growth 
of P. acnes. These data demonstrate that chitosan-alginate NPs have antimicrobial activity 
against P. acnes, and that the antimicrobial activity of the NPs was due to the chitosan and 
not the alginate.
Friedman et al. Page 3
J Invest Dermatol. Author manuscript; available in PMC 2013 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Anti-inflammatory effects of the chitosan-alginate nanoparticles
Since chitosan has been shown to have various anti-inflammatory properties (Kim et al., 
2004)), we specifically investigated whether the inflammatory cytokines and chemokines 
induced by P. acnes could be modulated in the presence of chitosan-alginate NPs. Human 
monocytes were isolated from peripheral blood and stimulated cells with P. acnes in the 
presence of various concentrations of chitosan-alginate NPs. As shown in Figure 3a, P. 
acnes induction of cytokine IL-12p40, previously shown to be involved in the inflammatory 
response in acne, was inhibited by the chitosan-alginate NPs in a dose-dependent manner, 
demonstrating almost complete reduction IL-12 protein at the highest concentration of 
chitosan-alginate NPs tested. Similarly, human keratinocytes HaCaT cells were cultured, 
stimulated with P. acnes in the presence of various concentrations of chitosan-alginate NPs. 
We found that the induction of IL-6 by P. acnes in keratinocytes were inhibited in the 
presence of chitosan-alginate NPs almost completely, even at a low dose concentration 
(Figure 3c). Chitosan-alginate NPs did not have a toxic effect on human monocytes as 
demonstrated in the MTT assay (Figure 3b) while sodium chromate, a positive control, had a 
significant cytotoxic effect on human monocytes. On the other hand, there was mild toxicity 
to HaCaT cells at higher concentration of NPs, however when compared to subclinical 
concentrations of benzoyl peroxide, this impact was insignificant (Figure 3d). Therefore, our 
data suggest that the chitosan-alginate NPs can inhibit P. acnes induced cytokine production 
in human monocytes and keratinocyte and this is not simply due to the release of cytokines 
at cell death.
Chitosan-alginate nanoparticles as a delivery vehicle for topical therapeutics
While chitosan alone shows antimicrobial activity against P. acnes, the use of chitosan-
alginate NPs provides the benefit of incorporating multi-therapeutics. Benzoyl peroxide 
(BP) has both a mild keratolytic and potent bactericidal effect to which P. acnes has yet to 
demonstrate resistance (Dutil, 2010). Although an effective acne therapy, skin irritation is an 
expected but an unwanted adverse event, and is frequent at efficacious doses. Therefore, 
encapsulation in nanoparticles could be one approach to improving efficacy by reducing the 
side effects associated with topical application and ultimately improving patient compliance. 
In addition, benzoyl peroxide and chitosan together may provide superior antimicrobial 
effect against P. acnes when combined in this format, each providing a different mechanism 
of action. Benzoyl peroxide (0.1%) was encapsulated into chitosan-alginate NPs and 
incubated with P. acnes prior to plating and determination of bacterial viability. 
Encapsulation of BP into NPs demonstrated enhanced antimicrobial activity against P. acnes 
at several concentrations tested (Figure 4a). The encapsulated BP exhibited a synergistic 
antimicrobial activity against P. acnes in comparison to NPs and BP alone at several 
concentrations tested. Furthermore, encapsulated BP demonstrated less toxicity against 
eukaryotic cells than BP alone (Figure 4b), suggesting that the encapsulation of BP within 
the chitosan-alginate NPs may provide protection for eukaryotic cells.
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Chitosan-alginate nanoparticles and nanoparticle encapsulated benzoyl peroxide induce 
cell wall disruption of P. acnes
To determine the mechanism by which the chitosan-alginate NP induces the killing of P. 
acnes, bacteria that were treated with chitosan-alginate NPs were examined using both 
scanning eletron microscopy (SEM) and transmission electron microscopy (TEM). The 
SEM photographs of untreated P. acnes illustrated the bacterium's normal structure 
demonstrating the smooth and intact cell wall (Figure 5). A higher magnification TEM 
image revealed the normal cell wall structure of P. acnes with well-demarcated outer and 
inner dark lipophilic layers and a lighter hydrophilic peptidoglycan layer in the center. When 
the bacteria were treated with chitosan-alginate NPs, the P. acnes’ cell wall appeared light, 
suggesting loss of lipids. Higher magnification TEM imaging demonstrated that the cell 
membranes lost their lipophilic “sandwich-like” normal appearance. In addition, the low 
TEM and SEM imaging revealed damage to the cytoplasm.
The BP treated bacteria also experienced some damage to the cell wall and membrane. 
There was loss of the normal cell wall structure and clustering of the membrane’s lipophilic 
components into droplets with loss of normal cytoplasmic features. However, the addition of 
NP encapsulated BP to P. acnes resulted in greater perturbation of the cell as compared to 
native BP (0.1%). The TEM and SEM images revealed severe disruption and destruction 
and “peeling” of the cell wall. Many cells appeared to have lost their cytoplasmic contents. 
The lipophilic portion of the membrane showed alteration of the structure and formation of 
relatively larger lipophilic globules as well as a wider, edematous space within the cell wall. 
These images suggest that the cell damage is due to an osmotic disturbance.
Discussion
In this paper we synthesized chitosan-alginate NPs and demonstrated that they are 
therapeutically multi-faceted. Chitosan-alginate NPs demonstrated potent antimicrobial 
activity against P. acnes. Chitosan-alginate NPs were shown to induce bacterial cell wall 
membrane disruption as demonstrated by electron microscopy, suggesting a mechanism for 
NP antimicrobial activity. The chitosan-alginate NPs also exhibited anti-inflammatory 
properties as they inhibited P. acnes induced inflammatory cytokine IL-12 production in 
human monocytes and IL-6 production in human keratinocytes. While chitosan alone 
exhibits potent antimicrobial activity against P. acnes, it’s therapeutic use can be 
challenging due to the solubility limitations of native chitosan. The chitosanalginate NP can 
therefore overcome this limitation yet still provide potent antimicrobial activity and 
furthermore can be utilized as a delivery system to incorporate additional therapeutics. Thus, 
the NP encapsulation of benzoyl peroxide, a common yet clinically irritating acne 
therapeutic, resulted in increased antimicrobial activity in comparison to benzoyl peroxide 
alone, while at the same time reducing toxicity to eukaryotic cells. Our data suggest that the 
chitosan-alginate NPs may be useful for the treatment of dermatologic conditions with 
infectious and inflammatory components such as acne vulgaris.
The treatment of cutaneous infections has been complicated by the emergence of microbial 
species that are resistant to standard antibiotic regimens(Spellberg, 2011; Spellberg et al., 
2011). This evolving medical challenge is of particular significance in the treatment of one 
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of the most common cutaneous skin disease, acne vulgaris. The gram-positive bacteria P. 
acnes and to a lesser extent P. granulosum and P. parvum are present and contribute to acne 
lesions (Zaenglein and Thiboutot, 2003). They produce enzymes and lipases that promote 
comedo rupture, comedogenic and proinflammatory factors, and glycocalyx polymers, 
which acts as adhesive that causes further aggregation of keratinocytes (Bellew et al., 2011). 
In addition, P. acnes activates immune cells to produce inflammatory mediators. Therefore, 
targeting both P. acnes and its associated inflammation is key to optimal therapy. In the 
setting of increasing resistance to standard antimicrobial therapy, innovative antimicrobial 
agents and approaches are needed (Kinney et al., 2010). The nanoparticle platform described 
was formed by combining the biostructural polymer chitosan with sodium alginate. Alginate 
is a family of polysaccharides composed of α-l-guluronic acid (G) and β-d-mannuronic acid 
(M) residues, arranged in homopolymeric blocks of each type (MM, GG) and 
heteropolymeric blocks (MG). Alginates form strong complexes with polycationic material, 
which stabilize this gel like material and reduce its porosity. Among those polycations, 
chitosan has received considerable attention due to its cationic characteristics as chitosan has 
the ability to gel on contact with counter anions (Coppi and Iannuccelli, 2009; Coppi et al., 
2001). Chitosan’s amino groups are able to interact with an anionic polymer that has 
carboxylic groups, such as alginate by ionic binding. Using electron microscopy, we 
demonstrated that nanoparticles measuring approximately 50 nm in diameter were formed.
Interestingly, when suspended in water, the particles swell to almost seven times their initial 
size, similarly witnessed by previous investigators (Gelfuso et al., 2011; Luo et al., 2011; 
Murugeshu et al., 2011). As chitosan is a hydrophilic polymer that presents amine groups in 
its chemical structure, it can form hydrogen bonds with water. Therefore, in the presence of 
water, chitosan nanoparticles can undergo swelling, forming a gel layer around the particles 
due to chitosan hydration. This swelling increases the diameter of these particles likely 
influencing the mechanism of drug release. For example, the benzoyl peroxide can diffuse 
through the swollen particle. Therefore, consideration must be given when translating this 
technology to the vehicle in which these nanoparticles are suspended in order to effectively 
control the rate of swelling and therefore release of therapeutics (Martinac et al., 2005).
Although the exact mechanism of how chitosan-alginate NPs kill microbes is unclear, we 
demonstrated through transmission and scanning electron microscopy osmotic disruption of 
the P. acnes cell membrane. Chitosan by itself is known to strongly adhere to negatively 
charged surfaces due to its high charge density at pH < 6.5. The interactions between the 
polycationic chitosan and the electronegative charges on the cell surfaces are thought to 
trigger perturbations in membrane integrity, leading to alterations in cell permeability (Chen 
et al., 1998). This interaction can lead to the leakage of intracellular electrolytes and 
proteinaceous components. Many endogenous cationic peptides, including granulysin, 
human beta-defensins, and cathelicidins, are thought to interact with the negatively charged 
microbe cell wall to induce killing. The advantage of using these molecules that target 
conserved membrane structures versus enzyme antagonists is the low possibility of microbe 
resistance, given the low probability of a single mutation leading to altered bacterial 
membrane structure. However, it has been shown that in certain environment, S. aureus can 
express surface protein IsdA, to become less hydrophobic and thus resistant to skin innate 
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defenses (Clarke et al., 2007), underscoring the growing need for novel approaches to 
antimicrobial therapies.
Work by other investigators has shown that chitosan has antimicrobial activities against 
various pathogens including bacteria, fungi and viruses, suggesting a broad antimicrobial 
spectrum (Alburquenque et al., 2010; El-Sharif and Hussain, 2011; Jayakumar et al., 2011; 
Potara et al., 2011; Tayel et al., 2010). Despite distinctive differences between gram-
negative and gram-positive bacteria, an antibacterial agent’s first interaction with its target 
will be at the cell surface, compromising either the cell wall or outer membrane. For gram-
positive bacteria, lipoteichoic acid could provide a molecular linkage for chitosan at the cell 
surface, allowing it to disturb membrane functions (Raafat et al., 2008). Lipopolysacchride 
and proteins in the gram-negative bacteria outer membrane are held together by electrostatic 
interactions with divalent cations that are required for its integrity and stabilization. 
Chitosan’s polycations may compete with divalent metals for binding with polyanions as 
well as has the potential to chelate important biologic metals (Kong et al., 2008). 
Replacement of Mg2+ and Ca2+ ions present in the cell wall likely disrupt the integrity of the 
cell wall or influence the activity of degradative enzymes. These data underscore the 
additional benefit of utilizing chitosan-derived NPs for drug delivery.
The chitosan-alginate NPs were also found to have immunomodulatory activity, inhibiting 
the production of inflammatory cytokine IL-12p40 and IL-6 by P. acnes stimulated 
monocytes and keratinocytes, respectively. P. acnes is a potent stimulator of host immune 
responses and because inflammation is a key pathogenic element of acne, it is tempting to 
speculate that the anti-inflammatory activity of NPs is the result of inhibition of the TLR2 
pathway, given the role of TLR2 activation in P. acnes induced cytokine and other pro-
inflammatory mediators (Jugeau et al., 2005; Kim et al., 2002; Nagy et al., 2005). Past 
studies have provided insight into chitosan’s ability to inhibit inflammatory cytokines and 
chemokines. It was shown that chitosan can inhibit NF-κβ activation in human mast cell 
lines through downmodulation of CA2+ induced mast cell activation (Seo et a., 2003) and 
suppression of mRNA expression of membrane metalloproteinases 1 and 3 (Kim et al., 
2004), suggesting that chitosan interferes with the Toll-like receptor signaling pathways. 
Additionally, it has been shown that IL-6 can play a role as a regulator of extracellular 
matrix deposition via MMPs and is involved in the immune response to P. acnes; as a 
consequence, it may be an important determinant of acne and therefore downregulation 
could be an important component of therapy(Pajulo et al., 1999). The anti-inflammatory 
effects of chitosan-alginate NPs suggest a possible role as immune modulating agents that 
could be translated to clinical use in infectious and other diseases with unwanted 
inflammatory reactions.
Due to chitosan’s polycationic nature as well as high affinity to metal, it has been employed 
as a carrier system and platform stabilizer for a variety of nanoparticle systems including 
metallic nanoparticles (Chadwick et al., 2010), nitric oxide-releasing nanoparticles 
(Friedman et al., 2008), and drug-containing nanoparticles which allows for targeted 
delivery of various medications (Qi et al., 2005). By combining this property with chitosan’s 
inherent antimicrobial action, using chitosan as a delivery platform for antimicrobial agents 
could potentially augment the antimicrobial properties of these agents. For example, the 
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antimicrobial efficacy of silver-loaded membranes is enhanced with increasing chitosan 
contents of up to 70%, resulting in larger zones of inhibition against both S. aureus and E. 
coli (Ma et al., 2008). Here, we sought to encapsulate and enhance the efficacy of benzoyl 
peroxide, a common therapy used for acne, in the chitosan-alginate NPs since bacterial 
resistance to benzoyl peroxide has not been reported to date. We found that nano-
encapsulation of benzoyl peroxide offers improved antimicrobial efficacy at lower and 
consequently less irritating and toxic concentrations, suggesting that the chitosan-alginate 
NP encapsulation of benzoyl peroxide may offer a highly effective therapeutic molecule 
with less irritation to the skin. In fact, the greatest damage to P. acnes cell wall occurred 
with NP encapsulated benzoyl peroxide. This is not surprising as benzoyl peroxide exerts its 
influence through oxidative stress and chitosan binds to the cellular membrane, altering 
permeability and structural stability.
Given the multifaceted impact of the NPs, the presented data inspire future in vivo studies to 
translate this technology to clinical practice. While future studies most certainly include in 
vivo safety testing such as clinical, histological, and immunohistochemical evaluation 
following topical application, the utility of studying efficacy in an animal model is not clear 
given the lack of a established animal models. While rhino mouse model is occasionally 
used in the literature, it only addresses hyperkeratotic effect of acne pathogenesis and is 
typically not used for new therapeutic development(Mirshahpanah and Maibach, 2007). 
Anti-inflammatory in vivo models with Propionibacterium acnes has been reported (Fan et 
al., 2012), however, this model is also limited in that it is an intradermal injection of P. 
acnes, measuring a local, granulomatous, inflammatory response rather than a true 
multifactorial acne model encompassing the pilosebaceous unit. Finally, and from a 
translational standpoint, the FDA does not require in vivo acne model for efficacy in the 
development of therapeutics for acne, rather in vivo safety data is required for pre-clinical 
safety data, which will be pursued as mentioned above.
The known benefits of nano-drug delivery, including size, stability, and encapsulation of a 
great range of therapeutics (Mu and Sprando, 2010; Nasir, 2010; Schroeter et al., 2010), 
combined with our data that chitosan-alginate NPs have both antimicrobial and anti-
inflammatory properties suggest that chitosan-alginate NPs have the potential to serve as a 
topical class of antimicrobials for the treatment of acne vulgaris as well as other cutaneous 
infections and inflammatory conditions. Even more importantly, the combination of 
antimicrobial activities between chitosan and benzoyl peroxide limits the risk of the 
emergence of resistant species. Therefore, our findings suggest that the chitosan-alginate NP 
encapsulation, which offers enhanced antimicrobial and anti-inflammatory properties as well 
as the promise of controlled release, provides previously undescribed therapeutic 
opportunities including delivery of multidrug regimens to combat resistant microbes and 
inflammatory disease states.
Materials and Methods
Production of Nanoparticles
70.0 mg of alginic acid sodium salt (Sigma Aldrich, Inc., St. Louis, MO) was added to 100 
ml of dH2O (0.7 mg/ml) and magnetically stirred until dissolved. 15 mg of calcium chloride 
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(CaCl2, Acros Organics, Geel, Belgium) was then stirred into 20 ml of dH2O (0.75mg/ml). 
The 20 ml CaCl2 solution was added drop wise into the alginic acid solution via a 27.5 
gauge needle while the alginic acid solution was concurrently sonicated. Following 
administration of the CaCl2, sonication was maintained for 1 min. The new solution was 
stirred for 30 min. Following this, 7 mg of chitosan (> 85% deacetylated, Sigma Aldrich), 
dissolved in 20 ml hydrochloric acid (0.35mg/ml, pH 1.4 – 2.0) (Fisher Scientific, 
Pittsburgh, PA) was added drop wise via a 27.5 gauge needle into the alginic acid-CaCl2 
solution. The resulting mixture was stirred magnetically for 1 h and then allowed to settle 
over a 24 h time period.
After 24 h, the formed suspension was centrifuged at 4,000 rpm for 1 h. The supernatant was 
discarded with subsequent addition of 50 ml of dH2O. The suspension was again centrifuged 
at 4,000 rpm for 1 h and the past step was repeated twice. Due to aggregation of the 
particles, the suspension was extensively vortexed for 2 min then sonicated for 3.5 h.
Encapsulation of benzoyl peroxide
0.1 g of benzoyl peroxide (Sigma Aldrich) was dissolved into 100 ml of 20% ethanol 
(Sigma Aldrich) and spun for 1 h. 70.0 mg of alginic acid was added to the mixture and spun 
to dissolve. 1.5 mg of CaCl2 was stirred magnetically into 20 ml of ethanol (0.75 mg/ml). 
The 20 ml of CaCl2 solution was added drop wise into the alginic acid solution via a 27.5 
gauge needle while the alginic acid solution was concurrently being sonicated. Following 
administration of the CaCl2, sonication was maintained for 1 min. The new solution was 
stirred for 30 min. Following this, 7 mg of chitosan dissolved in 20 ml hydrochloric acid 
(0.35 mg/ml, pH 1.4 – 2.0) was added drop wise via a 27.5 gauge needle into the alginic 
acid-CaCl2 solution. The resulting mixture was stirred for 1 h and then allowed to settle over 
a 24 h. After 24 h, the now formed suspension was centrifuged at 4,000 rpm for 1 h. The 
supernatant was discarded and 50 ml of dH2O was added. The suspension was again 
centrifuged at 4,000 rpm × 1 h and the past step was repeated twice. Due to aggregation of 
the particles, the suspension was vortexed for 2 min then sonicated for 3.5 h.
CFU assay
P. acnes strain ATCC 6919 (American Type Cell Culture, Manassas, Virginia) was grown 
under anaerobic conditions in Reinforced Clostridial Medium (Oxoid, Basingstroke, 
England) for 3 days and collected in mid-log phase. The bacteria were washed three times, 
suspended in 10 mM sodium phosphate, pH 7.2, supplemented with 0.03% trypticase soy 
broth (TSB, Becton-Dickinson, Cockeysville, Maryland), and enumerated by applying a 
conversion factor of 7.5 × 107 bacteria per ml=1 OD unit at 600 nm (Beckman DU® 640B 
Spectrophotometer, Beckman Coulter, Inc., Fullerton, CA). Various concentrations of 
alginate, chitosan, and chitosan-alginate NPs (1%, .5%, .2% .1%) were incubated with 3.75 
× 105 bacteria in a final volume of 30 Wl at 37°C for 4 h. After incubation, 10-fold dilutions 
were prepared and plated onto Brucella Agar supplemented with 5% sheep blood, hemin, 
and vitamin K (Remel, Lenexa, KS). Plates were incubated for 4 days at 37°C under 
anaerobic conditions. Individual colonies were counted and the number of CFU was 
tabulated.
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Electron Microscopy
P. acnes at a concentration of 2.08×107 bacteria per ml was suspended in 10 mM sodium 
phosphate buffer, pH 7.2, supplemented with 0.03% TSB and incubated with chitosan-
alginate NPs, BP 0.1%, [BP 0.1%] NP, and alginate as a control. Samples were then fixed 
for 30 min with 2% gluteraldehyde in 1x PBS, pH 7.35 at room temperature, then washed 
three times and suspended in 1 ml of 1x PBS. Scanning EM samples were filtered onto a 
micropore filter. The filters with the sample on top were dehydrated in graded ethanol: 50%, 
75%, 95%, and 100% for 15 min in each, followed by similar transfers in hexa-methyl-
disilazane reagent: 50%, 75%, 95% for 30 min each followed by 100% hexa-methyl-
disilazane reagent overnight. The scanning EM samples were gold coated then viewed and 
photographed on a Cambridge Scanning electron microscope. Transmission EM samples 
were dehydrated in graded ethanol as above, embedded in Epon, and sectioned on Sorvall 
MT6000 (RMC, Tucson Arizona). Thin sections (75 µm) were stained with uranyl acetate, 
viewed and photographed on Jeol XC100 at 80-kV.
Dynamic Light Scattering
A dilute suspension of chitosan alginate particles (0.1mg/ml) was sonicated and then the size 
of the particles were measured using dynamic light scattering (DLS). DLS measurement was 
performed using a DynaPro NanoStar (Wyatt Technology, Santa Barbara, CA) using an 
acquisition length of 5 seconds and a total of 40 acquisition attempts. An average particle 
hydrodynamic diameter (the diameter of the particle along with the shell of closely 
associated water molecules) and polydispersity was calculated from the results.
Primary human monocyte isolation and stimulation
Peripheral human blood was drawn from normal healthy volunteers into heparinized tubes 
according to a protocol approved by the Institutional Review Board at UCLA and gathered 
according to Declaration of Helsinki guidelines. Written consent was received prior to blood 
draw and use of material. PBMC were then isolated using Ficoll-Paque gradients 
(Amersham Biosciences, Piscataway, New Jersey) and plated (5 × 106 per well) in 24-well 
plates with RPMI media (Invitrogen, Grand Island, New York) containing 1% FCS (Omega 
Scientific, Tarzana, California) for 2 h at 37°C. Non-adherent cells were removed by 
washing three times with RPMI media. Adherent monocytes were cultured in RPMI 
containing 10% FCS and left untreated or incubated with alginate, chitosan, and chitosan-
alginate NPs for 1 h before the addition of P. acnes sonicate (1µg/ml) for 24 h at 37°C. 
Supernatants were harvested 24 h later and assayed for IL-12p40 by ELISA (BD 
Pharmingen, San Diego, CA). Human keratinocyte cell line, HaCaT cells were cultured with 
keratinocyte medica containing 1% FCS (Omega Scientific, Tarzana, California). Cells were 
cultured in RPMI containing 10% FCS and left untreated or incubated with alginate, 
chitosan, and chitosan-alginate NPs for 1 h before the addition of P. acnes sonicate (1µg/ml) 
for 24 h at 37°C. Supernatants were harvested 24 h later and assayed for IL-6 by ELISA 
(BD Pharmingen, San Diego, CA).
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MTT/MTS Toxicity Assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrasodium bromide tetrazolium (MTT, Sigma 
Aldrich) is a yellow water soluble compound processed by the mitochondria of live cells 
into a water insoluble purple formazan salt that can be measured at 570 nm. 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) assay reagent is used to measures dehydrogenase enzyme activity found in 
metabolically active cells. PBMC and HaCat cells were isolated as above and plated at 
2x105 cells per well in a 96-well plate for 2 h. Non-adherent cells were removed by washing 
twice with RPMI. In addition, HaCaT keratinocytes were also plated for 2h. Chitosan-
alginate NPs, BP 0.1%, and [BP 0.1%] NP were prepared in RPMI containing 10% FCS and 
50 µl of each compound was added to the wells containing PBMC. Chitosan-alginate NPs 
and BP 0.1% were added to the wells containing HaCat. All compounds were evaluated in 
triplicates, including a positive control of sodium chromate (20–100 µM) and media as the 
negative control. The wells were incubated at 37°C overnight. Within 24 h, the wells were 
washed twice with 200 µl of sterile 1x PBS. For the MTT, 100 µl of RPMI containing 10% 
MTT (5 mg/ml) and 10% FCS were added to each well and incubated for 4 h. Without 
washing, 100 µl of 10% SDS were added to each well and incubated for 8 h. Absorbance 
was measured at 570 nm using a microplate reader. For the MTS, 20µL of MTS assay 
reagent (Promega) was added to each well, and cells were incubated for 4 hours at 37°C. 
The absorbances were read at 490nm, with the number of viable cells absorbance 
proportional to absorbance. Treated wells were compared to the media control as percent of 
untreated media.
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NPs Nanoparticles
EM Electron Microscopy
CFU Colony Forming Unit
TLR Toll-like receptor
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BP Benzoyl Peroxide
[BP 0.1%] NP Benzoyl Peroxide 0.1% encapsulated into chitosan-alginate NPs
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Figure 1. Synthesis of chitosan-alginate nanoparticles
Nanoparticles were synthesized using chitosan and alginate. The structure was analyzed 
using (a) TEM (bar = 50 nm) and analytical sizing perform using DLS.
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Figure 2. Antimicrobial effects of chitosan-alginate nanoparticles
Various concentrations (1%, .5%, .2%, .1%) of chitosan-alginate NPs were incubated with 
P. acnes for 4 h and tested for antimicrobial activity using CFU assay (mean CFU/ml) and 
compared to chitosan and alginate as controls. These data are derived from eight 
independent experiments ± SEM (p-values: † ≤ 0.005, ‡ ≤ 0.001).
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Figure 3. Anti-inflammatory effect of chitosan-alginate nanoparticles
Chitosan-alginate NPs at various concentrations (6.5, 25 and 50 percent of stock, 
respectively) were incubated with primary human monocytes or HaCaT cells which were 
subsequently stimulated with P. acnes. (a) IL-12p40 and (c) IL-6 levels were determined by 
ELISA expressed by mean cytokine concentration (pg/ml) and are representative of four 
independent experiments + SEM (p-values: ** ≤ 0.01). (b,d) Cells were collected and 
evaluated for cell viability using a MTT (b) and MTS (d) assay. Data is expressed by mean 
percentage as compared to untreated cells and is composite of four independent experiments 
± SEM (b. pvalues: * ≤ 0.05, † ≤ 0.005, ‡ ≤ 0.001; d. p-values: * ≤ 0.05, ** ≤ 0.01, ≤ 
0.0001).
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Figure 4. Synergistic activity of benzoyl peroxide encapsulated chitosan-alginate nanoparticles
(a) Benzoyl peroxide encapsulated into chitosan-alginate NPs ([BP 0.1%] NP) were 
incubated with P. acnes for 4 h and tested for antimicrobial activity using CFU assay (mean 
CFU/ml) and compared to chitosan-alginate NPs, BP 0.1%, and alginate as a negative 
control. These data are composite of eight distinct experiments ± SEM (p-values: ** ≤ 0.01, 
† ≤ 0.005, ‡ ≤ 0.001). (b) Primary human monocytes were stimulated with BP 0.1%, [BP 
0.1%] NP, and Na2Cr2O7 as a positive control for toxicity, and evaluated for cell viability 
using MTT assay. Data is expressed by mean percentage as compared to untreated cells and 
is composite of three independent experiments ± SEM (p-value: ‡ ≤ 0.001).
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Figure 5. Effects of chitosan-alginate NP, benzoyl peroxide and NP encapsulated benzoyl 
peroxide on the cell structure of P. acnes.
SEM (bar = 1 µm), low power TEM (bar = 1 µm) and high power TEM (bars = 100 nm) 
demonstrated the effect of chitosan-alginate NP, benzoyl peroxide alone (BP 0.1%) and NP 
encapsulated BP ([BP 0.1%] NP) on P. acnes after 4 h of incubation with the bacteria. EM 
studies represent data from at least three different experiments.
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